Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2018 Sep 6

PMID 30181299

Citations 227

Authors

Jason E Hawkes

Bernice Y Yan

Tom C Chan

James G Krueger

Affiliations

Soon will be listed here.

Abstract

Psoriasis vulgaris is a common, heterogeneous, chronic inflammatory skin disease characterized by thickened, red, scaly plaques and systemic inflammation. Psoriasis is also associated with multiple comorbid conditions, such as joint destruction, cardiovascular disease, stroke, hypertension, metabolic syndrome, and chronic kidney disease. The discovery of IL-17-producing T cells in a mouse model of autoimmunity transformed our understanding of inflammation driven by T lymphocytes and associations with human inflammatory diseases, such as psoriasis. Under the regulation of IL-23, T cells that produce high levels of IL-17 create a self-amplifying, feed-forward inflammatory response in keratinocytes that drives the development of thickened skin lesions infiltrated with a mixture of inflammatory cell populations. Recently, the Food and Drug Administration approved multiple highly effective psoriasis therapies that disrupt IL-17 (secukinumab, ixekizumab, and brodalumab) and IL-23 (guselkumab and tildrakizumab) signaling in the skin, thus leading to a major paradigm shift in the way that psoriatic disease is managed.

Citing Articles

Neuroimmunology of psoriasis: Possible roles for calcitonin gene-related peptide in its pathogenesis.

Kotlyar J, Granstein R Brain Behav Immun Health. 2025; 44:100958.

PMID: 40008232 PMC: 11851231. DOI: 10.1016/j.bbih.2025.100958.

Memory Cells in Infection and Autoimmunity: Mechanisms, Functions, and Therapeutic Implications.

Giri S, Batra L Vaccines (Basel). 2025; 13(2).

PMID: 40006751 PMC: 11860616. DOI: 10.3390/vaccines13020205.

Autoimmune disease and risk of lymphoma: analysis from real-world data and Mendelian randomization study.

Zhan L, Chen S, Liu Y, Lu T, Yu Z, Wang X BMC Cancer. 2025; 25(1):351.

PMID: 40000981 PMC: 11863826. DOI: 10.1186/s12885-025-13754-4.

Alloferon and IL-22 receptor expression regulation on the pathogenesis of imiquimod-induced psoriasis.

Agura T, Jo H, Shin S, Jang Y, Choi C, Gwak I Sci Rep. 2025; 15(1):6671.

PMID: 39994364 PMC: 11850768. DOI: 10.1038/s41598-025-90961-w.

The IL-23/Th17 pathway inhibitors in the treatment of psoriasis and the risk of skin malignancies: a review.

Krzysztofik M, Brzewski P, Kulbat A, Masajada M, Richter K, Wysocki W Postepy Dermatol Alergol. 2025; 41(6):552-559.

PMID: 39877117 PMC: 11770571. DOI: 10.5114/ada.2024.143428.

References

Boyman O, Hefti H, Conrad C, Nickoloff B, Suter M, Nestle F . Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med. 2004; 199(5):731-6. PMC: 2213300. DOI: 10.1084/jem.20031482. View

Reich K, Armstrong A, Foley P, Song M, Wasfi Y, Randazzo B . Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III,.... J Am Acad Dermatol. 2017; 76(3):418-431. DOI: 10.1016/j.jaad.2016.11.042. View

Papp K, Tyring S, Lahfa M, Prinz J, Griffiths C, Nakanishi A . A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005; 152(6):1304-12. DOI: 10.1111/j.1365-2133.2005.06688.x. View

Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles K, Tian S, Cardinale I . Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2010; 131(3):677-87. DOI: 10.1038/jid.2010.340. View

Nickoloff B, Bonish B, Huang B, Porcelli S . Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci. 2000; 24(3):212-25. DOI: 10.1016/s0923-1811(00)00120-1. View

Hueber W, Sands B, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins P . Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012; 61(12):1693-700. PMC: 4902107. DOI: 10.1136/gutjnl-2011-301668. View

Gudjonsson J, Johnston A, Dyson M, Valdimarsson H, Elder J . Mouse models of psoriasis. J Invest Dermatol. 2007; 127(6):1292-308. DOI: 10.1038/sj.jid.5700807. View

Blauvelt A, Papp K, Griffiths C, Randazzo B, Wasfi Y, Shen Y . Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active.... J Am Acad Dermatol. 2017; 76(3):405-417. DOI: 10.1016/j.jaad.2016.11.041. View

Bettelli E, Sullivan B, Szabo S, Sobel R, Glimcher L, Kuchroo V . Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J Exp Med. 2004; 200(1):79-87. PMC: 2213316. DOI: 10.1084/jem.20031819. View

10.

Langley R, Elewski B, Lebwohl M, Reich K, Griffiths C, Papp K . Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014; 371(4):326-38. DOI: 10.1056/NEJMoa1314258. View

11.

Mease P, McInnes I, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D . Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med. 2015; 373(14):1329-39. DOI: 10.1056/NEJMoa1412679. View

12.

Papp K, Langley R, Lebwohl M, Krueger G, Szapary P, Yeilding N . Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008; 371(9625):1675-84. DOI: 10.1016/S0140-6736(08)60726-6. View

13.

Harden J, Johnson-Huang L, Chamian M, Lee E, Pearce T, Leonardi C . Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis. J Allergy Clin Immunol. 2014; 135(2):553-6. DOI: 10.1016/j.jaci.2014.05.046. View

14.

Lew W, Bowcock A, Krueger J . Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol. 2004; 25(6):295-305. DOI: 10.1016/j.it.2004.03.006. View

15.

Hawkes J, Gudjonsson J, Ward N . The Snowballing Literature on Imiquimod-Induced Skin Inflammation in Mice: A Critical Appraisal. J Invest Dermatol. 2016; 137(3):546-549. PMC: 5326590. DOI: 10.1016/j.jid.2016.10.024. View

16.

Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C . The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun. 2014; 5:5621. DOI: 10.1038/ncomms6621. View

17.

Gottlieb A, Blauvelt A, Thaci D, Leonardi C, Poulin Y, Drew J . Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018; 79(2):302-314.e6. DOI: 10.1016/j.jaad.2018.04.012. View

18.

Lowes M, Bowcock A, Krueger J . Pathogenesis and therapy of psoriasis. Nature. 2007; 445(7130):866-73. DOI: 10.1038/nature05663. View

19.

Torres T, Romanelli M, Chiricozzi A . A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs. 2016; 25(7):751-4. DOI: 10.1080/13543784.2016.1187130. View

20.

Aggarwal S, Ghilardi N, Xie M, de Sauvage F, Gurney A . Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2002; 278(3):1910-4. DOI: 10.1074/jbc.M207577200. View